Clinical Trials Logo
  1. Home
  2. Thalassemia Major
  3. NCT01740531

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

Thalassemia Major Clinical Trial

Official title:
A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

Clinical Trial Summary

To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who require chronic transfusion support due to thalassemia major.

Clinical Trial Description

To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who require chronic transfusion support due to thalassemia major. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01740531
Study type Interventional
Source Cerus Corporation
Contact
Status Completed
Phase Phase 3
Start date December 2012
Completion date December 31, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Recruiting NCT02126046 - Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major N/A
Completed NCT01125254 - Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Phase 2/Phase 3
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Completed NCT00733811 - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Phase 4
Enrolling by invitation NCT02986698 - In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Phase 1
Not yet recruiting NCT06026839 - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
Terminated NCT00007072 - Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major Phase 2
Completed NCT04292314 - Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia Phase 2/Phase 3
Completed NCT02049450 - Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. Phase 2
Active, not recruiting NCT04523376 - Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies N/A
Completed NCT03992001 - Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients Phase 4
Not yet recruiting NCT05777733 - NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major Phase 1
Completed NCT01241357 - High-Tc Susceptometer to Monitor Transfusional Iron Overload Phase 2
Completed NCT00749515 - Pilot Study for Patients With Poor Response to Deferasirox Phase 4
Completed NCT04260516 - The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major Phase 1
Recruiting NCT02307786 - Long Term Outcomes in β Thalassemia Major N/A
Not yet recruiting NCT01323608 - The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Phase 4
Completed NCT00005893 - Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders N/A
Recruiting NCT06137079 - "Iron Overload and Endocrinological Diseases"